Actively Recruiting
Study of SKYVaricella4 NBP608 Vaccines Safety and Immune Response in Children 12 Months to 12 Years Using Two Dose Regimens
Led by SK Bioscience Co., Ltd. · Updated on 2026-09-15
780
Participants Needed
14
Research Sites
46 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety and immune response of an investigational varicella vaccine called NBP608 in healthy children aged 12 months to 12 years. The study compares NBP608 with licensed varicella vaccines to understand how well it works and how safe it is. This Phase III, randomized, double-blinded, multinational study involves children from multiple centers. Participants will be randomly assigned to receive either one of two potencies of NBP608 or one of two licensed varicella vaccines. Each participant will receive one or two subcutaneous injections of the study vaccine. The study includes a two-dose regimen, and the vaccines are administered via injections under the skin. The study period lasts about 15 months, during which participants will have seven clinic visits and follow-up phone calls after each vaccination to monitor safety. Throughout the study, researchers will collect blood samples at set times to measure immune response to the varicella virus. Safety is monitored by tracking adverse events, serious adverse events, and special interest events after vaccination. Participants and their parents or guardians will attend scheduled visits and receive follow-up calls to report any side effects. The main outcomes measured include rates of immune response and antibody levels six weeks after each dose and six months after the second dose.
CONDITIONS
Brief Title
SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years
Research Team
B
Bora Kim
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here